Treatment of Remitting-Relapsing Multiple Sclerosis (MS) With Cladribine: Results of an Open Pilot Study at 18 Months

Journal of Neurology - Germany
doi 10.1007/bf02444017
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Springer Nature

Related search

Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Cladribine for Highly Active Relapsing Multiple Sclerosis

Prescriber
Pharmacology
2018English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England

Journal of Medical Economics
Health Policy
2018English

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
1999English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Multiple Sclerosis International
Neurology
2015English

PND14 Budgetary Impact of the Treatment of Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy